Using Anticholinergics to Treat Overactive Bladder: The Issue of Treatment Tolerability
- 31 March 2006
- journal article
- review article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 119 (3), 9-15
- https://doi.org/10.1016/j.amjmed.2005.12.011
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: A subanalysis of data from the OPERA trialAmerican Journal of Obstetrics and Gynecology, 2005
- A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladderBJU International, 2005
- TROSPIUM CHLORIDE IMPROVES OVERACTIVE BLADDER SYMPTOMS: A MULTICENTER PHASE III TRIALJournal of Urology, 2004
- Darifenacin, an M3 Selective Receptor Antagonist, is an Effective and Well-Tolerated Once-Daily Treatment for Overactive BladderEuropean Urology, 2004
- Management of Overactive BladderNew England Journal of Medicine, 2004
- Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU International, 2004
- Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding studyBJU International, 2003
- The newer antimuscarinic drugs: bladder control with less dry mouth.Cleveland Clinic Journal of Medicine, 2002
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCEJournal of Urology, 1999